

FY2024 HIGHLIGHTS



"Ipsen delivered solid results and advanced its pipeline in 2024, laying a strong foundation for sustained growth"

David Loew


Chief Executive Officer

2025 Financial Guidance^{1,2}


Total sales growth greater than 5.0%³ (at CER)

Core operating margin Greater than 30.0%⁴ of total sales


FY 2024 TOTAL SALES



GEOGRAPHIC BREAKDOWN



TOTAL FY2024 SALES BY THERAPY AREA AND MEDICINE



2024 PIPELINE DEVELOPMENTS - APPROVALS

- U.S. approval – Onivyde in 1L PDAC
- E.U. approval - Iqirvo in 2L PBC
- E.U. approval - Kayfanda in ALGS

OTHER

- Sale of rare pediatric disease Priority Review Voucher
- Divestment of Increlex[®] (mecasermin injection)

For further information on Ipsen's FY 2024 financials results update and definitions of financial indicators, please refer to the press release at:

Alina Levchuk

Vice-President, Investor Relations
+41 79 572 8712
alina.levchuk@ipsen.com

Nicolas Bogler

Senior Manager, Investor Relations
+33 6 52 19 98 92
nicolas.bogler@ipsen.com

1: Excluding any impact from potential late-stage (Phase III clinical development or later) external-innovation transactions.

2: Guidance on total sales and core operating margin is based on accelerated sales growth of the ex-Somatuline portfolio and assumes negative impact on Somatuline sales due to increased generic competition in the U.S. and Europe.

3: Based on the average level of exchange rates in Jan 2024, a favorable effect on total sales of about 1% from currencies is expected.

4: Includes additional R&D expenses from anticipated early and mid-stage external-innovation opportunities

2L: second line; PBC: primary biliary cholangitis; ALGS: Alagille syndrome; NETs: neuroendocrine tumors.

All growth rates are at constant exchange rates.